1. Generics Bulletin
  2. >>Products

Adalvo Celebrates Unique European Nod For Prolonged-Release Pregabalin

Launch Imminent For ‘First Once-Daily Pregabalin Formulation’ Value Added Medicine

 
• By Dave Wallace

Adalvo, the B2B unit of the Alvo group of companies, has announced a successful decentralized European approval for its pregabalin prolonged-release tablets, with a launch imminent. The “milestone” for its value added medicines program could allow the firm to offer what it has previously billed as “the first once-daily pregabalin formulation.”

Added Value
Adalvo said the approval was a milestone for its value added medicines strategy • Source: Shutterstock

Adalvo, the B2B unit of the Alvo group that also includes sister companies Alvogen and Alvotech, has announced a European approval through the decentralized procedure for its pregabalin prolonged-release tablets.

CEO Anil Okay described the launch of the “first and only pregabalin controlled-release” in Europe as “one of the many...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin